Palladiem’s Novo Nordisk NVO Stock Holding History

Palladiem’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,279	Closed	-$117K	–	166
2025 Q4	$117K	Buy	+2,279	New	+$117K	0.11%	70
2023 Q3	$506K	Sell	5,568 -150	-3%	-$13.2K	0.55%	30
2023 Q2	$463K	Hold	5,718	–	–	0.48%	32
2023 Q1	$455K	Hold	5,718	–	–	0.49%	30
2022 Q4	$387K	Hold	5,718	–	–	0.4%	34
2022 Q3	$285K	Sell	5,718 -30	-0.5%	-$1.61K	0.3%	37
2022 Q2	$320K	Sell	5,748 -2,250	-28%	-$125K	0.32%	37
2022 Q1	$444K	Hold	7,998	–	–	0.39%	33
2021 Q4	$448K	Hold	7,998	–	–	0.36%	33
2021 Q3	$384K	Hold	7,998	–	–	0.31%	33
2021 Q2	$335K	Hold	7,998	–	–	0.27%	44
2021 Q1	$270K	Sell	7,998 -1,382	-15%	-$49.2K	0.24%	42
2020 Q4	$328K	Buy	+9,380	New	+$324K	0.31%	40
2015 Q3	$43K	Hold	1,600	–	–	0.07%	51
2015 Q2	$44K	Hold	1,600	–	–	0.04%	62
2015 Q1	$43K	Hold	1,600	–	–	0.04%	72
2014 Q4	$34K	Buy	+1,600	New	+$35.7K	0.03%	80

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

DAM

Diamant Asset Management Ridgefield, Connecticut $147M AUM 25.76% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Palladiem's NVO Position: Q1 2026 in Review

Palladiem sold out of Novo Nordisk (NVO) in Q1 2026, closing a stake of 2,279 shares — an estimated $117K sold.

Palladiem first reported a position in NVO in Q4 2014 and held it in 17 quarters. The position peaked at $506K in Q3 2023. 1,277 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

Palladiem reported no remaining Novo Nordisk position as of Q1 2026 after selling out during the quarter.
Palladiem sold 2,279 Novo Nordisk shares in Q1 2026, an estimated $117K.
Palladiem first reported a position in Novo Nordisk in Q4 2014 and held it in 17 quarters.
Palladiem's Novo Nordisk position peaked at $506K in Q3 2023.
1,277 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Palladiem's 13F filing for Q1 2026, filed 6 May 2026.